Celladon Corporation Receives Patent from United States Patent and Trademark Office

Patent will further expand intellectual property protection for MYDICAR® - a first in class drug under clinical evaluation for advanced heart failure

SAN DIEGO. -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,221,738 with claims that cover the administration of MYDICAR, Celladon's first in class drug under clinical evaluation for advanced heart failure. The patent, titled "Methods of enhanced uptake of viral vectors in the myocardium" carries a patent term to at least March, 2030. A similar application has been filed with the EU Patent Office (EPO).

"This is yet another important addition to our evolving patent portfolio for MYDICAR. The allowance further strengthens MYDICAR's market exclusivity protection in the United States" said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp. "This is the second important patent granted to MYDICAR this year and we will continue the pursuit of additional patent grants relevant to our products on a global basis."

Source: Celladon Corporation

Celladon Corporation Receives Patent from United States Patent and Trademark Office

Patent will further expand intellectual property protection for MYDICAR® a first in class drug under clinical evaluation for advanced heart failure SAN DIEGO. Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases,
Industry News
2012-07-19T04:00:00Z

Comments